AmerisourceBergen Board Must Face Investors’ Syringes Lawsuit

Aug. 24, 2020, 8:25 PM

AmerisourceBergen Corp.’s board of directors must face a derivative lawsuit by investors over allegations they allowed the company’s Oncology Supply Pharmacy Services subsidiary unit to be run like a “criminal organization.”

  • Delaware Court of Chancery Vice Chancellor Sam Glasscock III on Monday denied the directors’ request to throw out the lawsuit filed on behalf of the company against the board
  • “The directors ignored such red flags as did exist, and, in addition, permitted a woefully inadequate reporting system with respect to the business line in which Pharmacy operated,” Glasscock said
  • The Pharmacy unit illegally used overfill quantities of oncological ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.